NASDAQ:JNCE
Jounce Therapeutics, Inc.
- Stock
1.88
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus